Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Así es como usted puede verificarlo

Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.

Los sitios web seguros .gov usan HTTPS
Un candado (  ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

La información sobre este estudio está en inglés.

Si necesita ayuda en español, comuníquese con el Centro de Educación y Referencias sobre la Enfermedad de Alzheimer y las Demencias Relacionadas (ADEAR, por sus siglas en inglés) por teléfono al 800-438-4380 o envíe un correo electrónico. También puede llamar o enviar un correo electrónico al contacto del estudio (en inglés) para obtener información adicional.

Find more clinical trials

T3D-959 for Mild to Moderate Alzheimer's Disease

Start: July 2015
End: June 2016
Enrollment: 36

What Is This Study About?

This study will assess the effects of the experimental drug T3D-959 in people with mild to moderate Alzheimer's disease. Changes in cognition, glucose metabolism in the brain, blood oxygen levels, and brain connectivity will be evaluated.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 90 Years

Must have:

  • Diagnosis of mild to moderate Alzheimer's disease 
  • Mini-Mental State Examination score of 14-26; Clinical Dementia Rating of 0.5 to 2.0; Modified Hachinski score of less than or equal to 4
  • Washout of psychoactive medications (other than antidepressants) at least 4 weeks before first testing
  • On stable dose of permitted medications for 4-12 weeks before first testing
  • Seeing and hearing ability adequate for neuropsychological testing
  • Caregiver to supervise taking medications

Must NOT have:

  • Diagnosis of diabetes, including use of diabetes medications, fasting plasma glucose level of >126 mg/dl, or hemoglobin A1c of >6.5 percent
  • Unable to participate in FDG-PET or MRI brain scan
  • Diagnosis of significant neurological/psychiatric disease other than Alzheimer's disease
  • History of moderate or severe congestive heart failure; cardiovascular event within the past 6 months
  • Pregnant or lactating
  • ALT and/or AST levels that are twice the upper limit of normal; bilirubin levels that exceed 2 mg/dL; serum creatinine >1.5 mg/dL in men or >1.4 mg/dL in women
  • Current or past severe or unstable medical or psychiatric disorder requiring treatment that may make the subject unlikely to complete the study
  • Prohibited medications: fluvoxamine, warfarin, certain highly protein-bound medications
  • Cancer within the last 5 years, other than nonmelanoma skin cancer; stable, nonprogressive prostate cancer not requiring treatment, or in situ cervical cancer
  • Known history of HIV, hepatitis B, or hepatitis C
  • Blood pressure greater than 160/100 mmHg
  • Known or suspected intolerance or hypersensitivity to the study drug, closely related compounds, or any of their ingredients
  • History of substance abuse or dependence (except nicotine dependence) within the past 2 years
  • Use of experimental amyloid-lowering therapies use within 2 months before first testing; participation in any other investigational study or received an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to first testing
  • Any surgical or medical condition that may significantly alter the absorption of any drug substance
  • Reside in hospital or moderate- to high-dependency continuous care facility
  • Nonambulatory or wheelchair-bound
  • History of swallowing difficulties

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: T3D Therapeutics, Inc.

Source: ID: NCT02560753

Un sitio web oficial del Gobierno de los Estados Unidos, gestionado por el Instituto Nacional sobre el Envejecimiento, parte de los Institutos Nacionales de la Salud